NCT04713202 2023-02-10
NET-PACS
Big Ten Cancer Research Consortium
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT04776876 2021-09-29
Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01172717 2013-07-26
Study of Panitumumab in the Treatment of Carcinoid Syndrome
Boston Medical Center
Phase 2 Withdrawn